Hi everyone, here is my weekly dealmaking update that focuses on good news across MedTech, Biotech, and Deep Tech. Some interesting deal news from VC funds, antibodies, cancer vaccines and more. Congratulations to everyone involved.
☑️ Omega Funds has raised $647 million for the investment shop’s latest round aimed at life sciences companies targeting unmet medical needs.
☑️ Otsuka Pharmaceutical is putting down $33 million cash for a Swedish biotech’s Cantargia IL1RAP antibodies designed to treat autoimmune and inflammatory diseases.
☑️ Alphabet spinoff SandboxAQ is teaming up with iOncologi to build a new mRNA vaccine for a common and aggressive brain tumor known as glioblastoma.
☑️ Coronary AI diagnostic developer Heartflow files $100M IPO
☑️ Numan, a UK leader in preventative digital healthcare, has raised £45m in fresh funding, led by Greece-based Big Pi Ventures, a multi-stage equity investor in technology businesses.
☑️ One Biosciences, a precision oncology biotech company pioneering clinical grade single-cell tumour transcriptomic profiling, has announced a €15 million Series A financing
☑️ A pair of CROs from opposite sides of the Atlantic Ocean are merging to form a global organization. Evestia Clinical and Atlantic Research Group are joining forces to bring clients expertise in oncology, immunology, neurology and late-stage clinical trials
☑️ The UK is establishing a new biosecurity centre designed to improve research into potentially pandemic-causing pathogens and protect against emerging public health threats, with the government committing £250m.
Let us know if we missed anything.
===============
Newton Colmore is a specialist search firm and we connect exceptional engineering and scientific talent with impactful companies, globally.
